美沙酮带回家用药的启动时机
该研究采用目标试验模拟的队列设计,利用加拿大不列颠哥伦比亚省2010–2022年观察数据,纳入完成阿片类激动剂治疗诱导、年龄≥18岁、非妊娠或监禁、无癌症治疗或姑息治疗史的个体,分为初治使用者和流行新使用者。比较无带回家用药与完成诱导后0–4周、5–12周、13–24周、25–52周启动带回家用药的策略,主要终点为全因死亡和治疗中断(处方剂量间隔≥5天)。在流行新使用者中,与无带回家用药相比,5–12周和13–24周启动带回家用药对死亡(ARD分别为-0.98和-0.82)和治疗中断(ARD分别为-5.29和-5.97)的获益最大,任何带回家用药均优于不带回家。
要点
- 流行新使用者中,完成诱导后5–12周启动带回家用药,78周死亡风险较无带回家用药绝对降低0.98%(95%CI -1.62至-0.33)。
- 流行新使用者中,完成诱导后13–24周启动带回家用药,78周治疗中断风险较无带回家用药绝对降低5.97%(95%CI -7.16至-4.78)。
- 完成诱导后0–4周启动带回家用药亦降低死亡(ARD -0.87,95%CI -1.51至-0.23)和治疗中断(ARD -2.04,95%CI -3.99至-0.10)。
- 完成诱导后25–52周启动带回家用药对死亡获益不显著(ARD -0.31,95%CI -1.05至0.44),但仍降低治疗中断(ARD -4.39,95%CI -5.37至-3.42)。
- 初治使用者中观察到相似模式,多重敏感性分析支持主要结果。
适用人群与场景
- 适用人群:年龄18岁及以上、完成阿片类激动剂治疗诱导、非妊娠、非监禁、无癌症治疗或姑息治疗史的阿片类使用障碍个体。
- 研究场景:加拿大不列颠哥伦比亚省社区药房每日目睹服药的背景下,比较带回家用药启动时机。
- 包括初治使用者(无阿片类激动剂治疗史)和流行新使用者(过去一个月内无阿片类激动剂治疗)。
诊断标准与关键阈值
- 治疗中断定义:处方剂量间隔持续5天或以上。
- 暴露分组:无带回家用药;完成诱导后0–4周、5–12周、13–24周、25–52周启动带回家用药。
处置流程与药物剂量
- 原文未提及具体药物剂量、给药途径、频次或目标值。
- 原文未提及带回家用药的具体实施方案或调整规则。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:采用目标试验模拟原则的队列研究,使用加拿大不列颠哥伦比亚省2010–2022年观察数据。
- 主要终点(流行新使用者,78周调整风险差ARD):死亡—0–4周启动 vs 无带回家 -0.87(95%CI -1.51至-0.23);5–12周 -0.98(95%CI -1.62至-0.33);13–24周 -0.82(95%CI -1.59至-0.06);25–52周 -0.31(95%CI -1.05至0.44)。
- 主要终点(流行新使用者,78周ARD):治疗中断—0–4周 -2.04(95%CI -3.99至-0.10);5–12周 -5.29(95%CI -6.82至-3.76);13–24周 -5.97(95%CI -7.16至-4.78);25–52周 -4.39(95%CI -5.37至-3.42)。
- 初治使用者中观察到相似模式;多重敏感性分析(样本限制、时间零点分类、时间线限制、处理残余混杂偏倚)支持主要结果。
证据类型、等级与局限
- 证据类型:观察性队列研究,采用目标试验模拟和克隆-删失-加权方法。
- 局限:观察性设计,存在残余混杂可能(原文通过敏感性分析处理);数据来源于加拿大不列颠哥伦比亚省单一地区;未提及证据等级或推荐强度。
对床旁实践的改变
- 对于完成美沙酮诱导的阿片类使用障碍患者,可考虑在完成诱导后5–12周或13–24周启动带回家用药,以最大程度降低死亡和治疗中断风险。
- 任何时点启动带回家用药均优于不带回家用药,但25–52周启动对死亡获益不显著。
- 适用人群需满足:年龄≥18岁、完成诱导、非妊娠、非监禁、无癌症治疗或姑息治疗史;不适用于妊娠、监禁、癌症治疗或姑息治疗患者。
- 原文未提及具体带回家用药的剂量、频次或监测方案,临床实施需结合当地指南。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Daily witnessed ingestion in community-based pharmacies is standard practice for methadone maintenance treatment for opioid use disorder in British Columbia, Canada. Whether this practice, compared with take-home methadone, may pose a barrier to sustained retention in treatment and its lifesaving benefits is not known.
OBJECTIVE: To assess the different initiation times of methadone take-home doses in terms of time to all-cause mortality and methadone discontinuation, defined as a gap in prescribed doses lasting 5 or more days.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study using principles of target trial emulation used observational data from British Columbia, Canada, 2010-2022. Both incident (no history of opioid agonist treatment [OAT]) and prevalent new-user (no OAT within the past month) designs were used. The study included individuals aged 18 years or older who completed OAT induction, were not pregnant or incarcerated, and had no history of cancer treatment or palliative care. Data analyses were conducted from March 5, 2025, to May 29, 2026.
EXPOSURE: Exposure strategies were (1) no take-home dosing, (2) take-home dose initiation within 0 to 4 weeks after completing induction, (3) take-home dose initiation within 5 to 12 weeks after completing induction, (4) take-home dose initiation within 13 to 24 weeks after completing induction, and (5) take-home dose initiation within 25 to 52 weeks after completing induction.
MAIN OUTCOMES AND MEASURES: Outcomes were time to all-cause mortality and methadone discontinuation. A clone-censor-weight approach was used to estimate the 78-week adjusted risk difference (ARD).
RESULTS: A total of 9788 incident users (median age, 34.1 [IQR, 27.2-44.1] years; 32.8% female) and 31 658 prevalent new users (median age, 36.9 [IQR, 29.7-46.2] years; 33.3% female) were included. Compared with no take-home dosing in prevalent new-user analysis, ARDs for the mortality outcome were -0.87 (95% CI, -1.51 to -0.23) for take-home dose initiation within 0 to 4 weeks after completing induction, -0.98 (95% CI, -1.62 to -0.33) for take-home dose initiation within 5 to 12 weeks after completing induction, -0.82 (95% CI, -1.59 to -0.06) for take-home dose initiation within 13 to 24 weeks after completing induction, and -0.31 (95% CI, -1.05 to 0.44) for take-home dose initiation within 25 to 52 weeks after completing induction. Compared with no take-home dosing in prevalent new-user analysis, the discontinuation outcome ARDs were -2.04 (95% CI, -3.99 to -0.10) for take-home dose initiation within 0 to 4 weeks after completing induction, -5.29 (95% CI, -6.82 to -3.76) for take-home dose initiation within 5 to 12 weeks after completing induction, -5.97 (95% CI, -7.16 to -4.78) for take-home dose initiation within 13 to 24 weeks after completing induction, and -4.39 (95% CI, -5.37 to -3.42) for take-home dose initiation within 25 to 52 weeks after completing induction. Similar patterns were observed among incident users. Multiple sensitivity analyses with sample restrictions, time-0 classifications, timeline restrictions, and addressing residual confounding bias supported the primary results.
CONCLUSIONS AND RELEVANCE: Results of this study suggest that initiating take-home methadone within 5 to 12 weeks and 13 to 24 weeks after completing induction resulted in the greatest benefits in reducing mortality and treatment discontinuation, although any take-home dosing was consistently better than no take-home dosing. These client-level benefits warrant consideration when refining clinical guidelines on take-home dosing.
参考来源
- Hossain MB, Min JE, Kurz M, et al. Timing of Initiation of Methadone Take-Home Dosing. JAMA Intern Med. 2026. PMID: 42709433. doi:10.1001/jamainternmed.2026.3904
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。